Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dana-Farber Brigham Cancer Center has a long history utilizing cellular therapies to treat blood cancers and blood disorders. Over more than 30 years, we have performed more than 11,180 hematopoietic stem cell transplants, the original form of cellular therapy. We continue to offer patients the latest treatments, including CAR T-cell therapy, other genetically-modified T cells, and cancer vaccines.
The Connell and O'Reilly Cell Manipulation Core Facility (CMCF) is a key part of our cellular therapy program, processing almost 1,400 cellular products each year, including cells for more than 600 adult and pediatric stem cell transplants. The CMCF supports more than 40 diverse active clinical research protocols, with a focus on translational research in stem cell transplantation and immune therapy for cancer.
Stem Cell Transplant Resources
Cellular Therapies Resources
Learn about Dana-Farber's participation in the ASH Annual Meeting
